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terms of the Creativ
share the work provObjective: Estimated numbers of children living with HIV determine programmatic
and treatment needs. We explain the changes made to the UNAIDS estimates between
2015 and 2016, and describe the challenges around these estimates.
Methods: Estimates of children newly infected, living with HIV, and dying of AIDS are
developed by country teams using Spectrum software. Spectrum files are available for
160 countries, which represent 98% of the global population. In 2016, the methods
were updated to reflect the latest evidence on mother-to-child HIV transmission
and improved assumptions on the age children initiate antiretroviral therapy. We
report updated results using the 2016 model and validate these estimates against
mother-to-child transmission rates and HIV prevalence from population-based surveys
for the survey year.
Results: The revised 2016model estimates 27% fewer children living with HIV in 2014
than the 2015 model, primarily due to changes in the probability of mother-to-child
transmission among women with incident HIV during pregnancy. The revised estimates
were consistent with population-based surveys of HIV transmission and HIV prevalence
among children aged 5–9 years, but were lower than surveys among children aged
10–14 years.
Conclusions: The revised 2016 model is an improvement on previous models.
Paediatric HIV models will continue to evolve as further improvements are made to
the assumptions. Commodities forecasting and programme planning rely on these
estimates, and increasing accuracy will be critical to enable effective scale-up and
optimal use of resources. Efforts are needed to improve empirical measures of HIV
prevalence, incidence, and mortality among children.
Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2017, 31 (Suppl 1):S13–S22Keywords: antiretroviral therapy, models, mother-to-child transmission,
paediatric HIV, seroprevalenceIntroduction
Globally, there has been widespread scale-up of services for
pregnant women living with HIV to improve their own
health and prevent HIV transmission to their children. As
a result of this scale-up, it is estimated that globally, the Copyright © 2017 Wolters Kluwe
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S14 AIDS 2017, Vol 31 (Suppl 1)The 2015 WHO guidelines recommend starting all
individuals living with HIV on ART [2], but only an
estimated 49% (42–55%) of children living with HIV
(CLHIV) received ART in 2015 [1]. Efforts are needed to
expand access to paediatric treatment and to accurately
estimate the number of CLHIV at national and global
levels to support paediatric ART programme planning
[3]. Accurate estimates of the extent of the paediatric HIV
epidemic are also necessary to forecast demand for HIV
commodities and age-appropriate antiretroviral formu-
lations; these estimates in turn inform the quantity
of paediatric antiretroviral drugs that need to be
manufactured and procured to ensure a reliable supply
of paediatric antiretrovirals, and also to better target
and prioritize the development of suitable paediatric
antiretroviral drug formulations [3]. The accuracy of
estimates is also becoming more important as the numbers
of vertically acquired infections decrease.
In 2015, an estimated 1.8 million (1.5–2.0 million)
children aged 0–14 years were living with HIV, an
estimated 150 000 (110 000–190 000) children were
newly infected, and 110 000 (84 000–130 000) children
died of AIDS-related causes [1]. These global estimates
are based on mathematical models, because robust
empirical data on numbers of CLHIV are limited, and
can never be completely comprehensive. Data are
particularly limited about the total number of infants
newly acquiring HIV infection, and about rates of
survival among CLHIV, particularly for children infected
postnatally (during breastfeeding).
Spectrum is a well established model that has generated
robust global AIDS estimates since 1999 [4]. The model is
primarily driven by adult HIV surveillance data, whereas
demographic and programme data are used to further
calculate the HIVepidemic among children. Since 2008,
the UNAIDS (Joint United Nations Programme on
HIV/AIDS) Reference Group on Estimates, Modelling
and Projections has held five consultations among expert
groups to address different challenges related to child
estimates (including reviewing the structure of the child
model, MTCT probabilities and survival on ART [5];
estimating ART needs among children [6]; re-evaluating
the estimated probabilities of MTCT [7] and, convened
with WHO, reviewing the model structure and assump-
tions) [8]. During each of these consultations, important
model modifications changed the estimated numbers
of new child HIV infections, CLHIV, and AIDS-related
deaths among children (see Annex 1, http://links.lww.
com/QAD/A999 for a description of previous adjust-
ments to the UNAIDS child HIV estimates).
In this study, we summarize key changes implemented
in the Spectrum child model between 2015 and 2016, the
research that informed these modifications, and compare
the modelled estimates to the best available empirical
data. We highlight limitations and persisting evidence Copyright © 2017 Wolters Kluwer Hgaps to be addressed in future model revisions as part of
the ongoing effort to obtain more accurate global and
national paediatric HIV estimates.Methods
Structure and parameters
The Spectrum AIDS impact module (AIM) estimates
children newly infected with HIV each year, progresses
them through a series of health states over time and
transitions surviving children to the adult model at
15 years (see Fig. 1).
The AIM module calculates HIV prevalence among
adults aged 15–49 years from prevalence trends, and is
described elsewhere [9]. HIV prevalence among pregnant
women is derived from age-specific HIV prevalence
and age-specific fertility rates among all women, with
adjustments for the effects of HIV infection on fertility
[10]. The child model only calculates new HIV infections
due to MTCTand assumes no new infections from other
sources other than MTCTamong children aged less than
15 years. Rates of transmission depend on maternal
CD4þ cell count for women who did not receive any
antiretroviral-based prophylaxis or treatment, and by type
of regimen for those who did receive antiretrovirals. For
women receiving lifelong ART (excluding women
receiving a temporary antiretroviral-based prophylaxis),
the duration of treatment during peripartum is categor-
ized as started before conception, more than 4 weeks
before delivery or less than 4 weeks before delivery.
Women on lifelong ART are assumed to remain on
therapy throughout breastfeeding, with a default dropout
rate of approximately 2% per month. If the country team
has data on dropout among breastfeeding women, they
can enter national dropout values.
Transmission probabilities
In 2012, a review of existing literature identified
32 studies to determine the probability of transmission
for women receiving no antiretroviral and those receiving
different antiretroviral regimens [11]. In 2015, an
additional 48 studies were added to the 2012 analysis
(see Annex 2, http://links.lww.com/QAD/A999 for a
full list of studies used for this analysis and a further
explanation of the regimen categories). The updated
transmission probabilities were included in the 2016
Spectrum model.
In the Spectrum model, transmission may occur in utero
or intrapartum (peripartum), or through breastfeeding
(postnatal). The model calculates the numbers of new
infections separately for peripartum HIV transmission
and postnatal transmission.
Figure 2 presents the changes to the probability of MTCT
between the 2015 and the 2016 round of HIV estimates.ealth, Inc. All rights reserved.
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Fig. 1. Pediatric HIV calculations in Spectrum AIDS Impact Module. Rectangular boxes are assumptions and pre-populated data
included in the Spectrum software. Rounded rectangular boxes are data that countries enter and update every year. Diamonds
reflect calculations.The peripartum values describe the probability of
transmission during pregnancy and delivery, and reflect
any lack of adherence that existed in the study settings
(for some cases, the adherence from the studies will
be better than adherence in the general population). The
postpartum values are monthly probabilities and are
multiplied by the approximate duration of breastfeeding
in months. Transmission due to an incident infection
during breastfeeding is modelled as a one-time risk and is
thus not included in Fig. 2. The transmission probability
for an incident infection during breastfeeding is 27%
(compared to 28% in the 2015 model).
The largest adjustment occurred in the assumption about
transmission among women with an incident infection
during pregnancy (previously 30%, revised to 18%). The
probability of 30% came primarily from one study in
South Africa [12]. The more recent review of available
data revised the probability after including data from
additional studies including two that found transmission
risk less than 15% among maternal incident infections
during peripartum.
Disease progression among children not receiving
antiretroviral therapy
After infection, the model progresses children separately
depending on the age at which infection occurs (at 0–6
months, 7–12 months or greater than 12 months after
birth). The median survival without treatment is less than
2 years for children infected perinatally, but increases to Copyright © 2017 Wolters Kluweapproximately 6 years for those infected through
breastfeeding at 0–6 months, 11 years for those infected
at 7–12 months and 14 years for those infected after
12 months [13,14] (see Annex 3, http://links.lww.com/
QAD/A999 for further description).
The model transitions CLHIV through a series of CD4þ
categories in the absence of ART. Children under 5 years
are followed through seven CD4þ cell percentage
categories. Newly infected children are allocated to
CD4þ cell percentage categories based on data from the
HIV Pediatric Prognostic Markers Collaborative Study
(HPPMCS) and Cross Continents Collaboration for Kids
[6,15] (see Annex 3, Table 3.1, http://links.lww.com/
QAD/A999). The distribution of new infections by
CD4þ cell percentage category and the progression
rates are assumed to be independent of timing of
transmission (peripartum versus postnatal), but are
dependent on age.
Eachyear, the HIV-infected paediatric population ages by 1
year and is subject to non-AIDS mortality, HIV-related
mortality and progression to a lower CD4þ category. At
age 5 years, children transition from CD4þ cell percentage
categories to CD4þ cell absolute count categories. The
transition is based on the CD4þ cell distributions reported
by HPPMCS for children at age 5 years (see Annex 3, Table
3.2, http://links.lww.com/QAD/A999). The HPPMCS
data are available for children aged 0 through 10 years. The
data for children aged 10 were assumed to apply to childrenr Health, Inc. All rights reserved.
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Fig. 2. Probability of HIV transmission by PMTCT regimen. Peripartum transmission is the probabilty of transmitting between a
mother and child during the pregnancy and delivery. Postpartum transmission is a monthly probability that is multiplied by the
expected duration of breastfeeding which varies for womenwithin the PMTCT programme and women not in the programmewho
are not likely to know their HIV status. The probability of transmission to the infant among women who are infected while
breastfeeeding is a one-time risk and is 27% (compared to 28% in the 2015 model). The sources for the 2015 model assumptions
are Rollins et al. [11], except for ART started during pregnancy which was updated after the study by Rollins et al.. The 2016model
assumptions were previously available in an unpublished report by Lynne Mofenson. PMTCT, prevention of mother-to-child
transmission.aged 11–14years due to a lackof alternative information on
CD4þ progression without ART.
Mortality rates and progression rates by CD4þ cell
category are specified by age group and age at infection.
These rates have been derived by fitting a cohort model to
paediatric survival patterns [16]. Mortality rates were
constrained to increase exponentially with lower CD4þ
cell category (see Annex 3, Table 3.3, http://links.lww.
com/QAD/A999 for the resulting mortality rates).
Children initiating antiretroviral therapy
The number of children (0–14 years) receiving ART in
each calendar year is based on programme data entered in
the model by country teams. The Spectrum model
calculates the number of children who must start ART
each year to match programme data, while taking into Copyright © 2017 Wolters Kluwer Haccount mortality of those on treatment. In the 2015
model, the age distribution of children starting on ART
was assumed to imitate the age distribution of when
children became eligible for ART under national ART
eligibility criteria. In the 2016 model, the age distribution
of initiating ART was adjusted to reflect the age
distributions from patient data collected through the
International Epidemiological Databases to Evaluate
AIDS (IeDEA) Consortium (www.iedea.org).
Data on children starting ART up to 15 years were used
from six IeDEA regions: Asia-Pacific; Caribbean, Central
and Latin America; and West, South, Central and East
Africa regions. In most cases, data were provided for the
year 2001 onward. All children who started ART for the
first time at the sites participating in the IeDEA network
were included [17–19]. Children who were transferredealth, Inc. All rights reserved.
Estimates of HIV among children Mahy et al. S17from other clinics were excluded because the dates
of earliest ART initiation were not reliable in most cases.
The IeDEA data were transformed into the age-specific
probability that a CLHIV who is not on ART will start
ART each year.
The number of CLHIV starting ART in each calendar
year and age group is calculated by subtracting the
programme reported number of children on ART from
the estimated number of CLHIV to estimate the number
of CLHIV not receiving ART, multiplying the estimated
number of CLHIV not on ART in each age group by the
empirical probability of starting treatment derived from
the IeDEA data, and adjusting the age distribution to the
correct number of children starting ART in that year.
This approach preserves the age pattern of starting ART
while adjusting the total number starting ART to match
programme records (see Annex 4, http://links.lww.com/
QAD/A999 for the resulting probability of starting ART
by age over time).
Survival of children receiving antiretroviral therapy
The survival of children on ART is also based on data
available from IeDEA. Data were obtained from over
48 000 children aged 0–10 years at the start of ART
receiving care in facilities participating in the IeDEA
collaboration. Programmatic data spanned up to 15 years
and were collected from the four regions in Africa, and
the Asia-Pacific and the Caribbean, Central and South
America regions. Mortality rates at 6, 12, 24 and more
than 24 months after ART initiation were produced and
trends in mortality over time were assessed. Mortality
rates were adjusted for potential biases due to under-
reporting of mortality among children disengaged from
care using data obtained from patient-tracking studies
or linkage with vital registries when available [20]. Annual
mortality rates were calculated by sex, age, CD4þ cell
percentage (for children aged 0–5 years at the start of
ART) or absolute count (for children aged 6–10 years at
the start of ART), and region. Data were not
disaggregated by sex, as sex was not found to be a
significant risk factor for mortality.
Model output (estimates)
Spectrum generates a number of results, including
numbers of new HIV infections, people living with
HIV, and AIDS-related deaths and their respective rates
by age and sex. With every version of the model, revised
estimates are generated for every calendar year, from
1970 through the last year of available input data.
Surveillance and programme data for 2015 were not
available to include in the models developed by countries
in 2015 (the 2015 model), and thus the final calendar
year with estimates from the 2015 model is 2014. For the
2016 model, the last year with available estimates is 2015.
Although it is possible to project the HIV epidemic with
Spectrum, however, that discussion is not included in
this study. Copyright © 2017 Wolters KluweModel validation
There are little empirical data to describe HIV among
children. We validated the 2016 Spectrum model
revisions by comparing MTCT risk at 4–6 weeks and
at the conclusion of breastfeeding using population-level
impact studies; and HIV prevalence among children aged
5–9 years and 10–14 years using prevalence measured
in population-based surveys. The studies were limited
to nationally representative, population-level, empirical
studies that reflect the impact of HIV on children. A
PMTCT impact study from Malawi was excluded as it
only measured outcomes from immunization clinics in
four districts [21] (see Annex 5, http://links.lww.com/
QAD/A999 for information on the validation studies).Results
Comparison of Spectrum estimates for calendar
year 2014
In 2016, Spectrum files were available for 160 countries
representing 98% of the global population. The
comparison of the estimates from the 2015 and 2016
models are shown in Fig. 3. For this comparison, we
describe the results for the calendar year 2014 because
2014 is the last year for which the 2015 model produces
estimates. The number of new infections in 2014 dropped
from 220 000 (190 000–260 000) in the 2015 Spectrum
model to 160 000 (130 000–220 000) in the 2016 model
– a 27% reduction. The most important reductions in
new child infections were during years in which HIV
incidence among women was estimated to be highest – in
the late 1990s and early 2000.
The revised assumptions about ART initiation in the
2016 model increased the estimated median age of
starting ART (see Annex 6, http://links.lww.com/
QAD/A999), and, in turn, a greater proportion of
CLHIV died before starting on ART. However, the lower
overall numbers of CLHIV resulting from lower MTCT
probabilities meant that the absolute number of AIDS-
related deaths among children was lower than in the 2015
model. The estimated number of children dying of
AIDS-related causes in calendar year 2014 was 150 000
(140 000–170 000) in the 2015 model and 120 000
(95 000–150 000) in the 2016 model.
Validation of Spectrum projections
Mother-to-child-transmission risk
Compared to two studies of population-level MTCT
rates, the 2016 modelled estimates are within the
confidence intervals (CIs), or comparable, to the study
results [22,23]. The modelled transmission rates for South
Africa at age 6 weeks in the calendar year 2011 was 4.0%,
whereas the transmission rate from the South African
Impact Assessment was 3.5% (2.9–4.1%) [22] (see Fig. 4).r Health, Inc. All rights reserved.
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Fig. 3. The number of children living with HIV, new HIV infections among children and AIDS-related deaths among children in
the 2015 model versus 2016 model. Estimates for 2015 are not available from the 2015 model because surveillance and
programme data were not yet available at the time the country developed the file in early 2015. Uncertainty bounds are available
for the 2016 model. They are excluded from the figures to simplify the presentation of the figure.In Zimbabwe, the study results are for children aged
9–18 months. Preliminary results from the most recent
Zimbabwe Demographic and Health Survey suggest that
in 2015, 23% of children (regardless of maternal HIV
status) were still breastfeeding at age 18 months [24],
suggesting that the study results could potentially Copyright © 2017 Wolters Kluwer Hunderestimate the final MTCT rate. In calendar year
2012, modelled estimates of MTCT risk at the end of
breastfeeding were the same as the transmission rate
from the Zimbabwe PMTCT study: 10.0% (95% CI
7.5–12.6%). In calendar year 2014, the model estimated
final transmission rate was 6.8%, whereas the studyealth, Inc. All rights reserved.
Estimates of HIV among children Mahy et al. S19transmission rate at 9–18 months was 4.8% (95% CI
3.4–6.3%).
HIV prevalence
Figure 5 compares paediatric HIV prevalence from
national surveys to modelled estimates, using the survey
year as the year of comparison. Among the 5–9-year age
group, the HIV prevalence rate from the 2016 model falls
within the CIs of the survey data for three countries
with available CIs. The results fall outside of the CIs for
Swaziland. For the age group 10–14 years, the prevalence
rates from the 2016 model are within the CIs of the survey
data for Kenya and marginally outside of the intervals
for South Africa. However, the modelled results are lower
than the survey data, and outside of the survey CI in
Mozambique and Swaziland. For Botswana, for which no Copyright © 2017 Wolters Kluwe
Fig. 4. Mother-to-child transmission rates based on studies from S
model results. In the South African study, the MTCT rate was m
approximately 6 weeks. In the Zimbabwe study, the MTCT rate
transmission rate is estimated at 36 months. MTCT, mother-to-chiCIs were available, the 2016 estimates were considerably
lower in both age groups than the survey HIV prevalence.Discussion
In 2016, UNAIDS introduced significant changes to
the models that estimate HIV among children aged
0–14 years. Our review has three main findings. First, the
2016 models estimate fewer new child HIV infections
since the start of the HIV epidemic. As a result, the
numbers of CLHIV and AIDS-related deaths were also
considerably lower. Comparing results for calendar year
2014, the estimated CLHIV is 27% lower in the 2016
model due to model refinements. This adjustment is
important for our global understanding of paediatric HIV
as it implies that fewer children were in need of ART, andr Health, Inc. All rights reserved.
outh Africa [15] and Zimbabwe [16] compared to the 2016
easured at 8 weeks, whereas the modelled estimate is for
was measured at 9–18 months, whereas the final modelled
ld transmission.
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Fig. 5. HIV prevalence among children aged 5–9 and 10–14 years.HIV prevalence rates from themodels are for the same year as
the survey was implemented (the year is listed next to the country name). For example, the prevalence rates from the Kenya AIDS
indicator survey are all for the year 2012. Sources: Kenya AIDS Impact Survey 2012, Mozambique AIDS Indicator Survey 2009,
Swaziland Demographic and Health Survey 2006, South African HIV Prevalence and Incidence Survey, Botswana AIDS Impact
Survey 2012 [17–21].thus ART coverage among children is similar to ART
coverage among adults [49% (42–55%) among children
versus 46% (43–50%) among adults, globally] [1].
Second, the results from the 2016 models are partially
consistent with empirical data from nationally represen-
tative population-level studies of MTCT risk in two
countries. A further study of MTCT by Silohol et al. [25]
compared a sub-national estimate from Spectrum to
empirical data from a demographic and surveillance site
and found consistency with the empirical data. However,
there are mixed results when comparing the estimates
with nationally representative HIV prevalence for the age
group 5–9 years and 10–14 years. The estimates appear
to underestimate prevalence among children aged 10–14
years. The number of CLHIV at older ages might be
underestimated, and more children might need ART than
the number currently projected.
Third, whereas the reduction in new infections was an
important driver in the adjusted number of CLHIV, the
age at ART initiation also had an important impact on Copyright © 2017 Wolters Kluwer Hestimating the survival of CLHIV due to the high
mortality in the first 2 years of life. This emphasizes the
importance of capturing the timing of diagnosis and ART
initiation by age group in the models to improve the
accuracy of the national and global estimates of CLHIV.
Limitations to the 2016 estimates remain. Data from the
IeDEA consortium on initiation of ART or survival on
ART might be biased due to the facilities included in the
network, where earlier identification and treatment,
combined with better retention, may lead to improved
clinical outcomes. The default distribution of when
children initiate ART, from the IeDEA consortium, was
found to be similar to programme data in two countries
with good paediatric ART scale-up (South Africa and
Tanzania, see Annex 7, http://links.lww.com/QAD/
A999 for a comparison of the IeDEA data to national
programme data); however, additional comparisons of the
age distribution of ART initiation are needed for other
countries and other regions. If the IeDEA data include
sites with higher-quality services, the current estimates
might overestimate survival among CLHIV.ealth, Inc. All rights reserved.
Estimates of HIV among children Mahy et al. S21Lack of empirical, representative data on outcomes of
children (such as loss-to-follow-up or disengagement
from care) is especially challenging. Estimates of new
child infections will be erroneous without adherence and
viral suppression data among pregnant or breastfeeding
women living with HIV. Few programs have conducted
an evaluation of MTCTrates after breastfeeding cessation;
if treatment adherence wanes over time outside of
the clinical trial setting, the long-term risk of HIV
transmission through breastfeeding may be underesti-
mated from the clinical trial data.
The programme data entered into the Spectrum files to
produce estimates includes the number of women who
received different antiretroviral regimens. Over time, as the
antiretroviral regimens for preventingMTCT have changed
and the availability of treatment has increased, and countries
have struggled to update their registries to capture the
required data. The uncertainty bounds in the current
models do not reflect the uncertaintyof the programme data
that are entered into the models. Programme data directly
impact the estimated new child infections, CLHIV, ART
coverage and AIDS-related deaths.
There is insufficient information of how fertility among
women living with HIV changes over time as fertility
norms in society change, ART coverage increases and
women’s perception of their survival changes. When
modelling HIVamong children, the number of pregnant
women living with HIV is the first calculation. The
precision of these numbers directly impacts the accuracy
of all subsequent estimates related to CLHIV. Research
is ongoing to understand the dynamics of changing
fertility for women living with HIV when they are on or
off ART [26]; those studies will improve the models in
the future.
Additional information to improve the models – including
improved PMTCT programme data, data to improve the
parameter assumptions or data against which tovalidate the
results – is needed. Even in countries with large surveys,
the CIs around paediatric HIV prevalence rates are large,
making it difficult tovalidate the estimates. Collecting HIV
prevalence among children in household surveys is only
appropriate in countries where adult (15–49 years) female
prevalence is 5% or more [27]. For countries with
prevalence below 5%, the sample size required to
accurately measure prevalence, including determining
trends over time, is prohibitively large. In addition, surveys
often do not capture the status of children who might have
died between birth and data collection.
As global and national estimates are improved, more
attention is required to optimize the use of estimates to
inform programme scale-up. Current global commodities
forecasting and national quantification exercises rely
on Spectrum estimates. As ART programmes evolve
with innovative testing strategies (multiple testing at Copyright © 2017 Wolters Kluwedifferent time points for infant diagnosis), broader use of
antiretrovirals (such as multidrug postnatal prophylaxis)
and increasing use of second-line drugs, new modelling
approaches for forecasting will need to be explored to
ensure that age-appropriate formulations, and test-kits are
delivered when needed in a timely manner.
Similarly, broader programme planning and provision of
services is largely based on the estimated number of
infants, children and adolescents in need of the different
services. As programmes shift toward differentiated care
and service delivery tailored to specific ages, accurate
estimates will be increasingly important. The potential
impact of inaccurate estimates is substantial.
The current global estimates of HIV among children are
based on the best data available. They are calculated with
more precision than previous models. The improvements
in our understanding of when children acquire HIV
infection, when they initiate ARTand survival of infected
children will continue to evolve in the future. As
additional empirical data are generated from more robust
and routine sources, our ability to validate the modelled
estimates on HIV among children will improve. Thus,
while the 2016 models produced our best estimates to
date, they include substantial uncertainty and are likely to
continue to evolve in the future. Efforts to improve these
models will be essential to support the global response and
reach the goal of an AIDS-free generation.Acknowledgements
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